Evidence map›Paper›PMID 41819055›Full record

ArticleJACC. Basic to translational science2026

Methylated PIH1D1 as a Heart-Specific Biomarker for Anthracycline-Induced Cardiac Remodeling in Breast Cancer Patients.

Po-Yen Hsu, Wan-Hong Huang, Yi-Yun Lee, Robert Passier, Szu-Chin Li, Chong-Lin Hong, Shih-Kai Hung, Hong-Yi Lin, Chun-Hung Lin, Chen-Yu Chien and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Po-Yen HsuDepartment of Biomedical Sciences, National Chung Cheng University, Chiayi, Taiwan; Epigenomics and Human Diseases Research Center, National Chung Cheng University, Chiayi, Taiwan; INSERM UMR 1260, Regenerative Nanomedicine, University of Strasbourg, FMTS (Fédération de Médecine Translationnelle de l'Université de Strasbourg), Strasbourg, France.
Wan-Hong HuangDepartment of Biomedical Sciences, National Chung Cheng University, Chiayi, Taiwan.
Yi-Yun LeeDepartment of Biomedical Sciences, National Chung Cheng University, Chiayi, Taiwan; Epigenomics and Human Diseases Research Center, National Chung Cheng University, Chiayi, Taiwan.
Robert PassierApplied Stem Cell Technologies, Department of BioEngineering Technologies, TechMed Centre, University of Twente, Twente, the Netherlands.
Szu-Chin LiDivision of Hematology and Oncology, Dalin Tzu Chi Hospital, The Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan; School of Medicine, Tzu Chi University, Hualian, Taiwan.
Chong-Lin HongDivision of Hematology and Oncology, Dalin Tzu Chi Hospital, The Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan.
Shih-Kai HungSchool of Medicine, Tzu Chi University, Hualian, Taiwan; Department of Radiation Oncology, Dalin Tzu Chi Hospital, The Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan.
Hong-Yi LinSchool of Medicine, Tzu Chi University, Hualian, Taiwan; Department of Radiation Oncology, Dalin Tzu Chi Hospital, The Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan.
Chun-Hung LinDivision of General Surgery, Dalin Tzu Chi Hospital, The Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan.
Chen-Yu ChienDivision of Cardiology, Dalin Tzu Chi Hospital, The Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan.
Yi-Da LiSchool of Medicine, Tzu Chi University, Hualian, Taiwan; Division of Cardiology, Dalin Tzu Chi Hospital, The Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan.
Hsiang-Chun LeeDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Lipid Science and Aging Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Laurent DésaubryINSERM UMR 1260, Regenerative Nanomedicine, University of Strasbourg, FMTS (Fédération de Médecine Translationnelle de l'Université de Strasbourg), Strasbourg, France.
Canan G NebigilINSERM UMR 1260, Regenerative Nanomedicine, University of Strasbourg, FMTS (Fédération de Médecine Translationnelle de l'Université de Strasbourg), Strasbourg, France. Electronic address: nebigil@unistra.fr.
Michael W Y ChanDepartment of Biomedical Sciences, National Chung Cheng University, Chiayi, Taiwan; Epigenomics and Human Diseases Research Center, National Chung Cheng University, Chiayi, Taiwan; Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: biowyc@ccu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anthracyclines, key chemotherapy agents, pose cardiotoxicity risks. In a 3-year study of 89 breast cancer patients treated with doxorubicin or epirubicin, more than 50% showed reduced left ventricular ejection fraction and progressive ventricular dilation. Although troponin-I flagged acute damage, it failed to predict long-term remodeling. Using a human methylome atlas, researchers identified 33 heart-specific methylated CpG sites and validated methylated PIH1D1 (mPIH1D1) as a novel biomarker. Elevated mPIH1D1 levels strongly correlated with ventricular dilation but not left ventricular ejection fraction decline, indicating its sensitivity to early cardiac remodeling. mPIH1D1 may complement troponin-I in risk assessment and cardiotoxicity management for patients undergoing anthracycline-based chemotherapy.

Indexed as

breast cancercardiotoxicityDNA methylationdoxorubicinPIH1D1

Identifiers

PMID41819055
PMCPMC12995573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.